|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,896.00 GBX | -1.63% |
|
-0.97% | +3.92% |
| 12/08 | Global drugmakers invest billions to boost US presence | RE |
| 11/08 | GSK plc : Jefferies reaffirms its Buy rating | ZD |
| Market Cap | 75.97B 103B 88.94B 83.26B 143B 9,789B 145B 976B 383B 4,900B 385B 377B 16,346B | P/E 2026 * |
14.1x | P/E 2027 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 95.05B 128B 111B 104B 179B 12,248B 182B 1,222B 479B 6,130B 482B 472B 20,451B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.67% | Yield 2027 * | 3.95% |
Last Transcript: GSK plc
| 1 day | -1.63% | ||
| 1 week | -0.97% | ||
| Current month | -1.84% | ||
| 1 month | -3.34% | ||
| 3 months | +2.79% | ||
| 6 months | -11.81% | ||
| Current year | +3.92% |
| 1 week | 1,894 |  | 1,972 |
| 1 month | 1,850.5 | | 2,096 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/7/26 | Sell | Executive/Senior Manager | -38,000 | 0.0009% | ||
| 22/7/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 14/7/26 | Buy | Chief Technology Officer | 660 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.63% | -0.97% | +35.04% | +38.29% | 104B | |
| -1.37% | +8.90% | +91.28% | +130.00% | 1,098B | |
| -0.77% | +1.91% | +49.46% | +49.44% | 631B | |
| +0.85% | +2.58% | +25.90% | +64.34% | 438B | |
| -1.13% | +3.13% | +49.78% | +39.13% | 368B | |
| -0.74% | +1.01% | +31.08% | +38.64% | 298B | |
| -1.22% | +0.89% | +7.32% | +7.38% | 251B | |
| -0.70% | +6.23% | +45.32% | +57.82% | 226B | |
| +0.34% | -0.13% | -4.77% | -50.50% | 209B | |
| +2.04% | +0.38% | +12.70% | +69.71% | 165B | |
| Average | -0.43% | +1,689.04% | +34.31% | +44.43% | 378.88B | |
| Weighted average by Cap. | -0.65% | +1,355.74% | +49.41% | +65.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.87B 39.75B 37.21B 63.89B 4,375B 64.97B 436B 171B 2,190B 172B 168B 7,305B | 35.6B 48.09B 41.67B 39.01B 66.98B 4,586B 68.11B 457B 179B 2,296B 181B 177B 7,659B |
| Net income | 5.56B 7.52B 6.51B 6.1B 10.47B 717B 10.64B 71.49B 28.01B 359B 28.22B 27.6B 1,197B | 6.53B 8.83B 7.65B 7.16B 12.29B 842B 12.5B 83.96B 32.89B 421B 33.14B 32.42B 1,406B |
| Net Debt | 19.08B 25.78B 22.34B 20.91B 35.91B 2,459B 36.51B 245B 96.07B 1,231B 96.78B 94.67B 4,105B | 16.24B 21.94B 19.01B 17.8B 30.56B 2,093B 31.07B 209B 81.77B 1,047B 82.37B 80.58B 3,494B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/08/26 | GBX 1,896.00 | -1.63% | 4,543,480 |
| 10/08/26 | GBX 1,927.50 | -1.68% | 5,929,763 |
| 07/08/26 | GBX 1,960.50 | +1.24% | 4,447,941 |
| 06/08/26 | GBX 1,936.50 | +1.10% | 3,139,064 |
| 05/08/26 | GBX 1,915.50 | +0.05% | 8,739,818 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
